Enhanced ubiquitin-dependent degradation by Nedd4 protects against α-synuclein accumulation and toxicity in animal models of Parkinson's disease

Davies, Sian E., Hallett, Penelope J., Moens, Thomas, Smith, Gaynor ORCID: https://orcid.org/0000-0003-4332-8383, Mangano, Emily, Kim, Hyoung Tae, Goldberg, Alfred L., Liu, Ji-Long, Isacson, Ole and Tofaris, George K. 2014. Enhanced ubiquitin-dependent degradation by Nedd4 protects against α-synuclein accumulation and toxicity in animal models of Parkinson's disease. Neurobiology of Disease 64 , pp. 79-87. 10.1016/j.nbd.2013.12.011

PDF - Published Version Available under License Creative Commons Attribution. Download (1MB)

Abstract

Parkinson's disease is a neurodegenerative disorder, characterized by accumulation and misfolding of α-synuclein. Although the level of α-synuclein in neurons is fundamentally linked to the onset of neurodegeneration, multiple pathways have been implicated in its degradation, and it remains unclear which are the critical ubiquitination enzymes that protect against α-synuclein accumulation in vivo. The ubiquitin ligase Nedd4 targets α-synuclein to the endosomal–lysosomal pathway in cultured cells. Here we asked whether Nedd4-mediated degradation protects against α-synuclein-induced toxicity in the Drosophila and rodent models of Parkinson's disease. We show that overexpression of Nedd4 can rescue the degenerative phenotype from ectopic expression of α-synuclein in the Drosophila eye. Overexpressed Nedd4 in the Drosophila brain prevented the α-synuclein-induced locomotor defect whereas reduction in endogenous Nedd4 by RNAi led to worsening motor function and increased loss of dopaminergic neurons. Accordingly, AAV-mediated expression of wild-type but not the catalytically inactive Nedd4 decreased the α-synuclein-induced dopaminergic cell loss in the rat substantia nigra and reduced α-synuclein accumulation. Collectively, our data in two evolutionarily distant model organisms strongly suggest that Nedd4 is a modifier of α-synuclein pathobiology and thus a potential target for neuroprotective therapies.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Medicine
Publisher:	Elsevier
ISSN:	0969-9961
Date of First Compliant Deposit:	11 June 2020
Date of Acceptance:	24 December 2013
Last Modified:	06 May 2023 19:02
URI:	https://orca.cardiff.ac.uk/id/eprint/106226

Citation Data

Cited 55 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item